The Future of PSMA-Targeted Radionuclide Therapy: An Overview of Recent Preclinical Research
Prostate specific membrane antigen (PSMA) has become a major focus point in the research and development of prostate cancer (PCa) imaging and therapeutic strategies using radiolabeled tracers. PSMA has shown to be an excellent target for PCa theranostics because of its high expression on the membran...
Saved in:
Main Authors: | Eline A.M. Ruigrok (Author), Wytske M. van Weerden (Author), Julie Nonnekens (Author), Marion de Jong (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2019-10-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Advances in <sup>177</sup>Lu-PSMA and <sup>225</sup>Ac-PSMA Radionuclide Therapy for Metastatic Castration-Resistant Prostate Cancer
by: Sui Wai Ling, et al.
Published: (2022) -
Preclinical evaluation of CXCR4 peptides for targeted radionuclide therapy in glioblastoma
by: Anthony Waked, et al.
Published: (2024) -
Synthesis and Evaluation of Two Long-Acting SSTR2 Antagonists for Radionuclide Therapy of Neuroendocrine Tumors
by: Sofia Koustoulidou, et al.
Published: (2022) -
Overview of the Most Promising Radionuclides for Targeted Alpha Therapy: The "Hopeful Eight"
by: Romain Eychenne, et al.
Published: (2021) -
A Review on Tumor Control Probability (TCP) and Preclinical Dosimetry in Targeted Radionuclide Therapy (TRT)
by: Kaat Spoormans, et al.
Published: (2022)